--- canonical_name: Aniracetam alternate_names: Ro 13-5057, N-anisoyl-2-pyrrolidinone, 1-(4-methoxybenzoyl)pyrrolidin-2-one, Ampamet, Draganon, Sarpul, Memodrin canonical_topic: Aniracetam for Health & Longevity short_topic_lc: aniracetam creation_date: 2026-0904-1151 creator_ai_fullname: Opus 5 ep_keywords: Racetams, Nootropics, Ampakines --- # Aniracetam for Health & Longevity
Evidence Review created on 09/04/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Ro 13-5057, N-anisoyl-2-pyrrolidinone, 1-(4-methoxybenzoyl)pyrrolidin-2-one, Ampamet, Draganon, Sarpul, Memodrin ## Motivation Aniracetam is a laboratory-made compound from the racetam family, a group of substances first developed in the 1960s and sold in several countries as memory medicines. It dissolves in fat rather than water, reaches the brain quickly, and is taken by mouth. Interest in it comes from reports that it sharpens focus and recall while also easing tension, a combination that few compounds claim. It was approved decades ago in parts of Europe and Asia for the mental and emotional symptoms that follow a stroke or accompany dementia, then later lost that standing in at least one market. Today it is sold mainly through the grey market for brain supplements, where it is not an approved ingredient and where laboratory testing has repeatedly found it in products that do not list it. This review examines what is actually known about aniracetam: how it acts in the brain, what the human trials measured and where they disagree, what is known about safety, dosing, sourcing, and monitoring, and how far any of it extends to adults who already function well and are looking to protect memory and mood as they age. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists sources that give a high-level overview of aniracetam and the compound class it belongs to. * [Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries](https://pubmed.ncbi.nlm.nih.gov/12070527/) - Nakamura, 2002 The fullest single account of aniracetam's pharmacology and animal-model results, written by a scientist at Nippon Roche, the manufacturer, so its favourable framing carries a direct commercial interest. * [Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders](https://pubmed.ncbi.nlm.nih.gov/8199398/) - Lee & Benfield, 1994 Summarises the dose-ranging and comparative trial programme in older adults with memory disorders, including the head-to-head against piracetam, and is the clearest source on absorption, metabolism, and tolerability. * [Piracetam and other structurally related nootropics](https://pubmed.ncbi.nlm.nih.gov/8061686/) - Gouliaev & Senning, 1994 A 407-reference survey of the whole racetam class through 1992, covering receptor binding, toxicity, and the negative findings, and the best single map of what the class does and does not do. * [Clinical efficacy of aniracetam, either as monotherapy or combined with cholinesterase inhibitors, in patients with cognitive impairment: a comparative open study](https://pubmed.ncbi.nlm.nih.gov/22070796/) - Koliaki et al., 2012 The largest clinical dataset on aniracetam: 276 patients followed a year on aniracetam, cholinesterase inhibitors (drugs that slow breakdown of the memory transmitter acetylcholine), both, or neither. * [Aniracetam: An Evidence-Based Model for Preventing the Accumulation of Amyloid-β Plaques in Alzheimer's Disease](https://pubmed.ncbi.nlm.nih.gov/38552113/) - Love, 2024 Sets out the hypothesis linking aniracetam to reduced amyloid plaque formation; useful because it makes the argument explicit and testable. Written from a commercial brain-health company. No priority source listed for this review — Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine, or Lifespan.io — has published a high-level overview of aniracetam. Web and on-site searches on 04/09/2026 returned nothing at all on foundmyfitness.com, peterattiamd.com, hubermanlab.com and chriskresser.com. The two hits that do exist are passing mentions: a [Life Extension Magazine member interview](https://www.lifeextension.com/magazine/2015/4/rick-rosner) in which the interviewee describes taking piracetam or aniracetam, and a Lifespan.io article that cites aniracetam only in a reference title. Neither discusses the compound in the depth this section requires, so the list above draws on primary and narrative-review literature instead. ## Grokipedia * [Aniracetam](https://grokipedia.com/page/Aniracetam) A current, heavily referenced overview covering chemistry, receptor pharmacology, the clinical trial record, and regulatory status in one place, useful for orienting before reading the primary literature. ## Examine * [Aniracetam](https://examine.com/supplements/aniracetam/) States plainly that human studies are lacking, and gives the dosing conventions used outside the clinic, 1,000–1,500 mg daily in divided doses with food, that the trial literature does not address. ## ConsumerLab No ConsumerLab article on aniracetam exists. The direct site search returned only recall notices in which aniracetam appears as an undeclared ingredient, plus general memory-supplement answers. ConsumerLab tests dietary supplements and does not cover prescription or unapproved drugs, which is aniracetam's regulatory status in the United States and its status as a prescription medicine in the European markets where it remains licensed. ## Systematic Reviews This section lists the systematic reviews and meta-analyses that include aniracetam as a named intervention. * [The treatment of cognitive dysfunction in dementia: a multiple treatments meta-analysis](https://pubmed.ncbi.nlm.nih.gov/29502274/) - Perng et al., 2018 Pools 235 studies in 44,854 patients; aniracetam sits inside the vascular-dementia symptomatic group that outperformed other treatment classes, so its individual contribution is not separable. The trade-off in this literature is one-sided: the claimed cognitive effect is represented, but no systematic review or meta-analysis addresses aniracetam's harms, tolerability, or the opportunity cost of using it in place of a licensed alternative. That side of the trade-off is unrepresented. ## Mechanism of Action Aniracetam's primary action is on AMPA receptors (AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; the fast glutamate receptors that carry most rapid excitatory traffic between brain cells). It binds away from the transmitter site and slows receptor desensitisation, so excitatory currents decay more slowly ([Isaacson & Nicoll, 1991](https://pubmed.ncbi.nlm.nih.gov/1660156/)); later structural work mapped where this class of modulator sits on the receptor ([Jin et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16192394/)). Secondary effects include activation of metabotropic glutamate receptors (a slower, amplifying glutamate family) and increased cortical release of acetylcholine, the transmitter most tied to attention and memory, plus dopamine and serotonin ([Shirane & Nakamura, 2001](https://pubmed.ncbi.nlm.nih.gov/11597608/)). A competing account questions whether the parent compound matters at all in an intact body. Oral aniracetam is almost completely hydrolysed during first passage through the liver, leaving nanogram-level plasma concentrations ([Tian et al., 2008](https://pubmed.ncbi.nlm.nih.gov/19025058/)); the metabolites N-anisoyl-GABA (GABA = gamma-aminobutyric acid, the brain's main calming signal) and p-anisic acid circulate instead ([Cai & Wang, 2012](https://pubmed.ncbi.nlm.nih.gov/22552003/)). On this reading, the receptor work describes a molecule that barely reaches the brain intact. Key pharmacological properties: half-life of the parent is roughly half an hour; selectivity is for modulating AMPA receptors rather than activating them directly, with no meaningful binding at adrenergic, muscarinic, serotonin, dopamine, or benzodiazepine sites ([Gouliaev & Senning, 1994](https://pubmed.ncbi.nlm.nih.gov/8061686/)); distribution is fat-soluble and brain-penetrant; metabolism is hepatic amide hydrolysis by carboxylesterases (enzymes that cleave ester and amide bonds), with no published cytochrome P450 (the liver's main drug-processing enzyme family) data. ## Historical Context & Evolution Aniracetam belongs to a line that starts with piracetam, synthesised in 1964 and described by its developers as the first "nootropic", a compound meant to improve cognition without sedating or stimulating. Hoffmann-La Roche produced aniracetam in the 1970s as Ro 13-5057, a fat-soluble analogue intended to be more potent at lower doses. Its original licensed use was not enhancement of healthy cognition: it was approved in Italy and Japan for the memory, mood, and behavioural symptoms that follow cerebral infarction (a stroke caused by a blocked artery) or accompany dementia. The clinical record from that period is genuinely split. A three-month Finnish trial at 1,000 mg daily found memory tests improved, but placebo improved equally, and clinical ratings showed no difference between groups ([Sourander et al., 1987](https://pubmed.ncbi.nlm.nih.gov/3103163/)). An Italian six-month multicentre trial at 1,500 mg daily found the treated group improved on behavioural measures while placebo declined steadily ([Senin et al., 1991](https://pubmed.ncbi.nlm.nih.gov/1822317/)). A Danish trial in workers with solvent-related cognitive complaints found one result favouring aniracetam and one favouring placebo across nineteen measures ([Somnier et al., 1990](https://pubmed.ncbi.nlm.nih.gov/2188276/)). Two things then changed. In 1991 the receptor mechanism was identified, redirecting industrial interest towards purpose-built glutamate modulators rather than aniracetam itself. Separately, later reviewers record that aniracetam and oxiracetam left clinical use ([Malykh & Sadaie, 2010](https://pubmed.ncbi.nlm.nih.gov/20166767/)). Neither event settles the earlier trials; it left the compound to the consumer nootropics market, where licensed indications and trial results are frequently conflated. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit reaches High: no human clinical endpoint has been reproduced across more than one trial, because the two positive dementia trials at 1,500 mg daily are offset by two null placebo-controlled trials at 1,000 mg daily. ### Medium 🟩 🟩 No benefit reaches Medium: outside those conflicting dementia trials the controlled human data are single-session laboratory challenge experiments read out on brain-wave and psychometric surrogates, and the remainder is uncontrolled open-label and case series. ### Low 🟩 #### Cognitive and Behavioural Symptoms in Mild-to-Moderate Alzheimer-Type Dementia ⚠️ Conflicted Two placebo-controlled trials at 1,500 mg daily reported better behavioural and memory scores over four to six months; two at 1,000 mg daily found nothing, one in solvent-exposed workers rather than dementia. Net reading: any benefit appears confined to the higher dose in diagnosed dementia. **Magnitude:** At 1,500 mg daily, 109 patients with probable Alzheimer-type dementia separated significantly from placebo on psychobehavioural scales by six months while the placebo group deteriorated steadily ([Senin et al., 1991](https://pubmed.ncbi.nlm.nih.gov/1822317/)), and 60 patients at the same dose improved on multiple psychometric tests at two and four months ([Canonico et al., 1991](https://pubmed.ncbi.nlm.nih.gov/1767242/)); the two 1,000 mg trials showed no separation from placebo ([Sourander et al., 1987](https://pubmed.ncbi.nlm.nih.gov/3103163/); [Somnier et al., 1990](https://pubmed.ncbi.nlm.nih.gov/2188276/)). The published reports give no effect size for these scales. #### Mood and Emotional Stability During Treatment for Cognitive Impairment In an open-label comparison, emotional state improved at three months and cognitive and functional scores held steady through twelve months, while the group on standard cholinesterase inhibitors declined. Without randomisation or a placebo group, selection and expectation effects cannot be separated from any drug effect. **Magnitude:** Across 276 patients followed for a year, the aniracetam group maintained all measured neuropsychological parameters at 6 and 12 months and improved significantly on emotional state at 3 months, while the comparator group on cholinesterase inhibitors deteriorated significantly on cognition at 12 months ([Koliaki et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22070796/)). No between-group effect size is reported. #### Sleep Duration When Combined With a Sedative-Hypnotic Medication A nine-patient uncontrolled series combined aniracetam with zopiclone, a sedative-hypnotic (sleep-inducing) medication, in older adults with stroke, dementia, or Parkinson's disease; most slept markedly longer. Uncontrolled design; the sedative alone could account for it. **Magnitude:** 7 of 9 patients (78%) achieved more than 50% prolongation of sleeping time ([Katsunuma et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9628149/)). #### Cognitive Performance in Healthy Adults Two small controlled challenge experiments in healthy volunteers found aniracetam, or its hydroxy metabolite, blunted the brain-wave and psychometric decline produced by induced oxygen shortage. Neither tested ordinary unchallenged performance, and studies in healthy mice and pigeons found no effect on learning, memory, or anxiety. **Magnitude:** Direction is protective and confined to the challenge condition: 10 healthy men given aniracetam intravenously showed attenuated hypoxia-induced brain-wave and psychometric deterioration ([Saletu & Grünberger, 1984](https://pubmed.ncbi.nlm.nih.gov/6434496/)), and a single 1,500 mg oral dose of its 3-hydroxy metabolite most reduced hyperventilation-induced decline ([Kraaier et al., 1989](https://pubmed.ncbi.nlm.nih.gov/2776818/)); unchallenged healthy animals showed no change at all ([Reynolds et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29946420/)). The published reports give no effect size. ### Speculative 🟨 #### Reduced Amyloid-β Accumulation Proposed mechanism only: aniracetam may raise brain-derived neurotrophic factor (a nerve-growth protein) and α-secretase (the enzyme that cuts amyloid precursor protein harmlessly). No human biomarker trial has tested this ([Love, 2024](https://pubmed.ncbi.nlm.nih.gov/38552113/)). #### Anxiety and Depressed Mood Basis is animal work only: aniracetam reduced fear and despair behaviours in aged rats and increased dopamine and serotonin release. No controlled human trial has measured anxiety or mood as a primary outcome ([Nakamura, 2002](https://pubmed.ncbi.nlm.nih.gov/12070527/)). #### Protection After Stroke or Head Injury Basis is animal and cell work only: aniracetam limited astrocyte (brain support cell) death under simulated stroke conditions ([Gabryel et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12387365/)). It also improved cognition after head injury in rats ([Baranova et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16928181/)). #### Attention and Impulsivity in Attention-Deficit/Hyperactivity Disorder Basis is rodent work only: aniracetam reduced hyperactivity and impulsivity in an attention-deficit/hyperactivity disorder mouse model ([Sun et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40118526/)). A later report found rebalanced prefrontal excitatory and inhibitory signalling ([Cui et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41644999/)). ## Benefit-Modifying Factors * **Baseline cognitive status:** The only clinical responders identified were patients scoring 15–25 on the Mini-Mental State Examination (a 30-point bedside cognition test). Healthy volunteers have been studied only under laboratory oxygen deprivation, so a ceiling effect at ordinary baseline cannot be excluded. * **Baseline kidney filtration:** Metabolite clearance drives exposure. In patients with creatinine clearance of 20–30 mL/min, metabolite half-life was 4- to 7-fold longer than in young volunteers ([Endo et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9062694/)), so reduced filtration raises and prolongs exposure. * **Genetic variation in ester and amide hydrolysis:** Aniracetam is cleaved by carboxylesterases CES1 and CES2 (liver enzymes that split ester and amide bonds) ([Takai et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9300133/)). Common low-activity CES1 variants would shift the parent-to-metabolite ratio, though this has never been tested. * **Sex:** No sex-based difference in benefit has been demonstrated. The controlled trials enrolled both sexes but reported no sex-stratified analysis, so any difference would currently be invisible rather than absent. * **Pre-existing health conditions:** Diagnosis mattered more than dose in the trial set: the same daily amount that helped in diagnosed dementia did nothing in workers with solvent-related cognitive complaints, suggesting the effect requires a specific cholinergic and glutamatergic deficit. * **Age:** Every positive trial was in adults aged roughly 65 and older. At the older end of that range, slower metabolite clearance may increase both effect and side-effect intensity, which is one reason lower starting doses are conventional in this group. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches High: no adverse event has been documented in more than one controlled trial, because the controlled trials reported tolerability only as pooled summary statements without event-level counts. ### Medium 🟥 🟥 #### Confusion and Agitation in Older Adults with Dementia In the one placebo-controlled trial that reported reasons for stopping treatment, confusion caused discontinuation four times as often on aniracetam as on placebo. The proposed mechanism is straightforward: aniracetam prolongs excitatory signalling, which an already impaired brain tolerates poorly. The other controlled trials summarised tolerability without listing individual events, so this remains the only quantified estimate. It occurred in older adults with diagnosed dementia and resolved when the drug was withdrawn. **Magnitude:** Treatment was interrupted for confusion in 4 aniracetam recipients versus 1 placebo recipient among 44 randomised patients over three months ([Sourander et al., 1987](https://pubmed.ncbi.nlm.nih.gov/3103163/)). ### Low 🟥 #### Gastrointestinal Upset, Headache, and Restlessness Across the racetam class these are the commonly reported complaints, and trial reports describe aniracetam as well tolerated without listing rates. Reports are uncontrolled and mostly retrospective. Aniracetam does not appear to raise liver enzymes, which distinguishes it from some older cognition drugs. **Magnitude:** Not quantified in available studies. No controlled trial published event-level incidence rates for these complaints, and the published reports give only pooled tolerability statements ([Lee & Benfield, 1994](https://pubmed.ncbi.nlm.nih.gov/8199398/); [Gouliaev & Senning, 1994](https://pubmed.ncbi.nlm.nih.gov/8061686/)). #### Exposure to Undeclared and Inaccurate Doses in Consumer Products Because aniracetam is sold outside any approved supply chain, the amount taken is often not the amount on the label. Testing of cognitive-enhancement supplements detected pharmaceutical-level aniracetam in products, several undeclared, together with other unapproved drugs in the same capsule. **Magnitude:** In 10 tested cognitive-enhancement supplements, servings delivered up to 502 ± 0.8 mg of aniracetam, 75% (9 of 12) of declared drug quantities were inaccurate, and individual products contained as many as four unapproved drugs ([Cohen et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34484905/)). ### Speculative 🟨 #### Lowered Seizure Threshold Basis is animal work only: aniracetam reversed the protective effect of seizure-blocking drugs in seizure-prone mice, implying it can make seizures easier to provoke. No human case is attributed to it ([Chapman et al., 1993](https://pubmed.ncbi.nlm.nih.gov/8453982/)). #### Blunting of Pain Relief From Centrally Acting Medications Basis is rodent work only: aniracetam and piracetam abolished the pain relief produced by several centrally acting medications in mice. Whether this transfers to human pain management is untested ([Galeotti et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8801601/)). #### Late-Day Activation and Disrupted Sleep Basis is mechanistic only: holding excitatory signalling open plausibly delays sleep onset when a dose lands late. The only human sleep data run the other way, from an uncontrolled sedative-combination series. #### Unknown Consequences of Sustained Glutamate Potentiation Basis is mechanistic only: prolonging excitatory signalling is the intended action, and no human study has run beyond twelve months. Cumulative effects on brain excitability are therefore unmeasured rather than shown to be absent. ## Risk-Modifying Factors * **Seizure history:** The animal seizure-threshold signal makes epilepsy the single most relevant modifier. Anyone taking a glutamate-blocking antiseizure medication faces a mechanistically direct antagonism, which shifts this from a theoretical to a plausible interaction. * **Baseline kidney and liver function:** Reduced creatinine clearance prolongs metabolite half-life 4- to 7-fold ([Endo et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9062694/)), and hepatic hydrolysis is the sole clearance route, so impairment of either organ raises exposure and side-effect intensity. * **Genetic variation in carboxylesterase activity:** Low-activity CES1 variants slow amide hydrolysis and would raise parent-compound exposure. No pharmacogenetic study of aniracetam exists, so this remains inference from the metabolic pathway rather than observation. * **Pre-existing cognitive impairment:** The confusion signal appeared exclusively in patients with diagnosed dementia. An already compromised brain appears least able to absorb additional excitatory drive without behavioural disturbance. * **Sex:** No sex difference in adverse events has been reported. The trials did not analyse safety by sex, so this is an absence of data rather than evidence of equivalence. * **Age:** Adults at the older end of the target range clear the metabolites more slowly and carry more cerebrovascular burden, the same combination in which the confusion signal appeared. ## Key Interactions & Contraindications * **Glutamate-blocking antiseizure medications (perampanel, and the experimental agents NBQX and GYKI 52466):** Caution to absolute contraindication in epilepsy. Aniracetam directly opposes their action at the same receptor, with loss of seizure protection as the consequence. No safe co-administration schedule is established. * **Sedative-hypnotics (zopiclone, zolpidem, benzodiazepines):** Monitor. The only human combination data show longer sleep when aniracetam is added to zopiclone, so additive sedation is possible. Mitigation is to keep the aniracetam dose unchanged when a hypnotic is started, and reassess morning alertness. * **Cholinesterase inhibitors (donepezil, rivastigmine, galantamine):** Caution. Both raise cholinergic tone, so additive nausea, cramping, and vivid dreams are plausible; the one open-label combination study reported no excess harm. Mitigation is to introduce one agent at a time. * **Centrally acting pain medications (morphine, tramadol, and related agents):** Monitor. Rodent work shows aniracetam abolishing their pain relief, so reduced analgesic effect is the theoretical consequence. Mitigation is to reassess pain control rather than escalate the opioid dose. * **Over-the-counter caffeine products (caffeine tablets, combination headache remedies, energy formulations):** Caution. Both increase cortical excitatory tone, and restlessness and disturbed sleep are the expected additive consequence. Mitigation is to separate them by several hours and cap total daily caffeine. * **Over-the-counter sedating antihistamines (diphenhydramine, doxylamine):** Caution. These block acetylcholine centrally and directly oppose aniracetam's cholinergic effect, with blunted response and additive confusion in older adults as the consequence. Mitigation is to substitute a non-sedating antihistamine. * **Other racetams and glutamate-modulating supplements (piracetam, oxiracetam, phenylpiracetam, omberacetam):** Caution. Stacking is common practice and produces additive excitatory load without any safety data; several are themselves unapproved drugs. Mitigation is to use one agent at a time. * **Choline donors (citicoline, choline bitartrate):** Monitor. Frequently combined to offset headache attributed to cholinergic demand; the additive effect is on cholinergic tone, and excess produces headache and nausea rather than preventing them. Mitigation is stepwise dose finding. * **Other interventions:** No interaction with light therapy, cognitive training, or exercise programmes has been studied. Aniracetam has no anticoagulant activity of its own, so the bleeding-risk caution attached to piracetam does not transfer without direct evidence. **Populations who should avoid Aniracetam:** * Anyone with epilepsy or a prior unprovoked seizure, and anyone taking perampanel * Pregnancy and breastfeeding, on the basis of absent human reproductive data * Severe hepatic impairment (Child-Pugh Class C), since hepatic hydrolysis is the only clearance route * Severe renal impairment (creatinine clearance below 30 mL/min), where metabolite accumulation is documented * Adults with moderate-to-severe dementia (Mini-Mental State Examination below 15), the group in which no benefit was seen and confusion was observed * Anyone under 18, for whom no human data of any kind exist ## Risk Mitigation Strategies * **Batch certificate of analysis before first use:** A batch certificate showing identity and assay by mass spectrometry is the standard check. It mitigates the documented risk of undeclared drugs and inaccurate label quantities in cognitive-enhancement products. * **Low starting dose with slow titration:** Protocols begin at 400 mg once daily, reaching 750 mg twice daily over two weeks if tolerated. Slow escalation mitigates confusion, restlessness, and headache, which are dose-related and appeared in the frailest trial participants. * **Liver and kidney baselines before starting:** Liver enzymes and estimated glomerular filtration rate are the relevant pre-treatment measurements. They mitigate accumulation risk in the impairment states where metabolite half-life is prolonged 4- to 7-fold. * **Last dose before mid-afternoon:** Dosing before roughly 3 p.m. mitigates the sleep disturbance expected from prolonged excitatory signalling, and preserves the ability to interpret sleep quality as a monitoring marker. * **One compound at a time for at least four weeks:** Avoiding concurrent racetams and choline donors during the first month mitigates the additive excitatory and cholinergic load and makes any adverse event attributable. * **Immediate discontinuation on new confusion, agitation, or twitching:** Abrupt discontinuation carries no documented withdrawal effect, so stopping mitigates the confusion signal and the theoretical seizure-threshold risk without a taper penalty. * **Reassessment at 12 weeks against a pre-recorded cognitive score:** A defined stopping point mitigates the largest practical risk, which is indefinite use of an unapproved compound on the strength of expectation rather than measured change. ## Therapeutic Protocol * **Standard clinical protocol:** 1,500 mg daily by mouth, split into two or three doses with meals, for a minimum of four months. This is the regimen used in the trials that reported benefit and summarised by [Lee & Benfield, 1994](https://pubmed.ncbi.nlm.nih.gov/8199398/). * **Alternative lower-dose protocol:** 400–750 mg once or twice daily with food, the convention documented on the Examine entry. It has no controlled support but is the schedule most commonly followed outside licensed medical use. * **Origin of each approach:** The 1,500 mg regimen comes from the Hoffmann-La Roche development programme and the Perugia-led Italian multicentre trial; the lower-dose schedule comes from the consumer nootropics literature, with the Examine entry its most cited source. * **Best time of day:** Morning and early afternoon. The compound prolongs excitatory signalling, and the only human sleep data involve deliberate combination with a sedative, so late dosing has no supporting rationale. * **Half-life and dosing frequency:** The parent compound's plasma half-life is about 0.5 hours ([Tian et al., 2008](https://pubmed.ncbi.nlm.nih.gov/19025058/)), far too short for once-daily coverage, which is why split dosing rather than a single dose is standard in every protocol. * **Taken with dietary fat:** Aniracetam is fat-soluble and poorly absorbed fasted. Every trial protocol dosed with meals, and taking it with a fat-containing meal is the single largest controllable determinant of exposure. * **Genetic considerations:** No pharmacogenetic dosing guidance exists. CES1 variants would in principle alter parent exposure; APOE4 (Alzheimer's risk gene), COMT (clears dopamine) and MTHFR (processes folate) have never been examined against aniracetam response. * **Sex-based differences:** None established. Trials enrolled both sexes without stratified reporting, so no sex-specific dose adjustment can be justified from the evidence. * **Age adjustment:** For adults at the older end of the target range, starting at half the standard dose is conventional, because metabolite elimination is prolonged 4- to 7-fold when kidney filtration is reduced. * **Baseline biomarker influence:** Response in the trials was seen only in those with an already impaired cognitive score. Kidney filtration governs exposure, so both cognition and filtration are checked before choosing a dose. * **Pre-existing conditions:** Diagnosed dementia is the only condition in which response was demonstrated. Hepatic or renal impairment lowers the appropriate dose, and epilepsy rules the protocol out entirely. ## Discontinuation & Cycling * **Intended duration:** Short- to medium-term. The longest human exposure documented is twelve months in an open-label series; nothing supports indefinite use, and no lifelong-use data exist for any racetam. * **Withdrawal effects:** None demonstrated. Abrupt withdrawal after 31 days of dosing produced no abstinence signs in a primate dependence study, in contrast to the barbiturate comparator ([Kuwahara et al., 1987](https://pubmed.ncbi.nlm.nih.gov/3570103/)). * **Tapering:** Not pharmacologically required. The half-life is roughly half an hour and no rebound phenomenon has been reported, so trials and the dependence study both used abrupt cessation without incident. * **Dependence potential:** Low on available evidence. The same primate study found no self-administration at three unit doses over seven weeks, indicating neither physical nor psychological dependence in that model. * **Cycling:** No evidence base. Tolerance has never been documented for aniracetam, so cycling schedules circulating in consumer use rest on analogy with stimulants rather than on any observation of waning response. ## Sourcing and Quality * **Regulatory reality first:** Aniracetam is not a lawful dietary ingredient in the United States. The FDA has stated in writing that aniracetam products "are not dietary supplements or conventional foods" and are unapproved new drugs ([Warning Letter: Peak Nootropics LLC aka Advanced Nootropics](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019)). * **Licensed pharmaceutical supply:** Where aniracetam remains a licensed medicine, notably as Ampamet in Italy, it is dispensed by prescription against a pharmacopoeial standard. That is the only supply route with enforced identity, purity, and content specifications. * **What to look for in a certificate of analysis:** Identity confirmed by mass spectrometry, assay within ±10% of label, a named third-party laboratory, batch and date matching the product, plus heavy-metal and residual-solvent results. Marketing claims of "lab tested" without a batch document mean nothing. * **Known contamination pattern:** Market surveillance across twelve national medicines laboratories found unauthorised nootropics sold mainly as supplements, most from the illegal market and several as bulk raw material ([Vanhee et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40558871/)). Undeclared co-ingredients are the norm, not the exception. * **Compounding pharmacies:** Not a solution in the United States. Compounders may only work from approved drug substances or recognised monograph ingredients, and aniracetam qualifies as neither, so any domestic compounded preparation is itself unlawful. * **Formulation:** Oil-based or lipid-containing capsules are preferred over loose powder. Aniracetam is fat-soluble and intensely bitter, and capsule formats both improve absorption consistency and remove the dosing error inherent in volumetric measurement of bulk powder. * **Who says so:** The FDA is cited here as a regulator whose members derive no revenue from the position it takes on aniracetam, and no professional or advocacy organisation's guideline is used as a source anywhere in this review. ## Practical Considerations * **Time to effect:** The trials that found benefit measured it at two to six months, not in days. Any same-day change is a pharmacological effect of a half-hour-half-life compound and is not what the trials measured. * **Common pitfall — dosing fasted:** Aniracetam is fat-soluble and every trial dosed with meals. Taking it on an empty stomach lowers and destabilises exposure, which is the most likely explanation for inconsistent self-reported responses. * **Common pitfall — importing dementia results:** The positive findings come from adults with diagnosed dementia scoring 15–25 on a bedside cognition test. Extending them to a high-functioning brain assumes a deficit that is not present. * **Common pitfall — trusting the label:** Independent analysis found three-quarters of declared drug quantities inaccurate in this product category ([Cohen et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34484905/)). Label dose is a weak proxy for delivered dose absent a batch certificate. * **Regulatory status:** Unapproved new drug in the United States, prescription medicine in parts of Europe, and withdrawn from routine clinical use elsewhere. Products containing it have been recalled, including for undeclared aniracetam ([FDA recall notice for a supplement containing undeclared aniracetam](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/modern-warrior-recalls-modern-warrior-ready-dietary-supplement-due-undeclared-14-dmaa-and-aniracetam)). * **Cost and accessibility:** The compound itself is inexpensive. The real access cost is legal and analytical: obtaining verified material outside a licensed prescription market requires paying for independent testing that often exceeds the price of the powder. * **Payer incentives:** The licensed alternatives aniracetam once competed against are now cheap generics, so no insurer or health system has a material financial stake in favouring or rejecting it, and guideline formation here is unlikely to be shaped by cost pressure. ## Interaction with Foundational Habits * **Sleep:** Direction is mixed and timing-dependent. The only human sleep data are an uncontrolled series in which aniracetam added to a sedative lengthened sleep; against that, prolonged excitatory signalling is a plausible route to late-day activation. Practical convention places the last dose before mid-afternoon. * **Nutrition:** Direct and potentiating. Aniracetam is fat-soluble, so absorption depends on taking it with a meal containing fat; taken fasted, exposure is lower and more erratic. Common practice pairs it with a choline source such as citicoline, a convention with no controlled human support. * **Exercise:** No direct interaction is documented in either direction, and no trial has measured performance, recovery, or muscle growth under aniracetam. The mechanistic link is indirect at most, through cortical dopamine release affecting perceived effort. No timing rule around training has any evidential basis. * **Stress management:** Potentiating on paper, unproven in people. Animal work reports reduced fear and despair behaviour alongside increased cortical serotonin, which would predict a calming effect, but no human trial has measured cortisol or a validated stress scale. Behavioural stress work therefore remains the load-bearing element. ## Monitoring Protocol & Defining Success Aniracetam has no established laboratory monitoring standard, so the useful panel is the one that confirms the organs clearing it are healthy and that the cognitive complaint being targeted has no reversible cause. Before the first dose, the liver enzymes alanine aminotransferase (ALT) and aspartate aminotransferase (AST) plus estimated glomerular filtration rate (eGFR, a calculation of how fast the kidneys filter blood) establish clearance capacity, because the compound is broken down in the liver and its metabolites leave through the kidneys, far more slowly in older people. Vitamin B12 and thyroid-stimulating hormone (TSH) identify treatable causes of memory complaints that would otherwise be read as a drug response. A validated cognitive scale before starting gives the only objective anchor for judging change. Ongoing: repeat the cognitive scale and liver enzymes at 12 weeks, then every six months, with eGFR annually. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | Montreal Cognitive Assessment (MoCA) score | 26–30 of 30 | Objective anchor for any claimed cognitive change | MoCA is a 10-minute paper cognition screen; add 1 point for 12 years or less of education. Same version and time of day each retest | | ALT | 10–26 U/L | Confirms the only clearance pathway is intact | Conventional laboratory upper limits run to 40–55 U/L, well above the functional target. Fasting sample; avoid within 48 hours of intense exercise | | AST | 10–26 U/L | Cross-checks liver signal and flags muscle origin | Conventional upper limit is around 40 U/L. Best paired with ALT; a raised AST with normal ALT usually points to muscle, not liver | | eGFR | 90 mL/min/1.73 m² or above | Metabolite half-life lengthens 4- to 7-fold as filtration falls | Conventional threshold for concern is 60; functional practice treats anything under 90 as worth tracking. Fasting sample, well hydrated | | Vitamin B12 | 500–900 pg/mL | Excludes a reversible cause of memory complaints | Conventional lower limit near 200 pg/mL misses functional deficiency. Pair with methylmalonic acid if the result is 300–500 pg/mL | | TSH | 0.5–2.0 mIU/L | Excludes thyroid-driven cognitive slowing | TSH is thyroid-stimulating hormone; conventional range extends to 4.5 mIU/L. Draw before 10 a.m., fasting, and away from biotin supplements | Qualitative markers are as important as the panel, because the trial endpoints were behavioural rather than biochemical: * Word-finding fluency in unrehearsed conversation * Time to settle into focused work at the start of a session * Emotional evenness under ordinary provocation, which was the endpoint that moved earliest in the open-label data * Sleep onset latency and number of night awakenings, tracked because late dosing is the most likely source of harm * Absence of new confusion, agitation, or muscle twitching, which are the stopping signals ## Emerging Research * **No registered trials of aniracetam:** A ClinicalTrials.gov search on 04/09/2026 by intervention and by free text returned no registered study of aniracetam, in any status. For adults considering it now, this means no confirmatory human evidence is scheduled to arrive. * **Nearest registered racetam-class activity:** [NCT06479629](https://clinicaltrials.gov/study/NCT06479629), a phase 4 randomised placebo-controlled trial of piracetam 800 mg three times daily in 60 adults with diabetic peripheral neuropathy, with cognitive score and serum brain-derived neurotrophic factor among its endpoints. * **Amyloid hypothesis awaiting a test:** [Love, 2024](https://pubmed.ncbi.nlm.nih.gov/38552113/) proposes that aniracetam shifts amyloid precursor processing through neurotrophic factor and α-secretase pathways. A biomarker trial in adults with early amyloid accumulation would strengthen or dismantle the case directly. * **Attention-deficit models gaining traction:** [Sun et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40118526/) and [Cui et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41644999/) report behavioural improvement and rebalanced prefrontal excitation and inhibition in mouse models, the most active current line and one that could support a new human indication. * **Replicated null findings in healthy animals:** [Elston et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25099639/), [Reynolds et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29946420/), and [Phillips et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31002681/) each found no cognitive or affective effect in animals without pre-existing impairment, the strongest current evidence against enhancement use. * **Metabolite-centred pharmacology:** Validated assays now quantify the main metabolite N-anisoyl-GABA in human plasma ([Cai & Wang, 2012](https://pubmed.ncbi.nlm.nih.gov/22552003/)). Establishing whether the metabolite or the parent carries the activity would decide whether oral dosing can reproduce laboratory receptor findings at all. * **Adulteration surveillance as an evidence stream:** [Cohen et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34484905/) and [Vanhee et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40558871/) show product-testing work becoming the main source of new human exposure data, which weakens rather than strengthens the case for consumer use. ## Conclusion Aniracetam is a fat-soluble laboratory-made compound, developed in the 1970s as a stronger relative of the first memory drug of its kind. It holds open the brain's fast excitatory signalling a little longer, and it is broken down almost entirely on its first pass through the liver, so what circulates is mostly its breakdown products rather than the compound itself. The human record is thin and divided. Trials in older adults with diagnosed memory disorders point in opposite directions, and the ones that found benefit used a higher daily amount than the ones that did not. Outside that group the controlled human work is limited to brief laboratory experiments in healthy volunteers whose oxygen supply was deliberately reduced; nothing has been tested in healthy adults going about ordinary life, and studies in healthy animals found no effect on learning or memory. Reports of calmer mood and better sleep come from studies without a comparison group. Short-term safety looks unremarkable, with confusion in frail older patients the one signal a controlled study quantified. The larger practical hazard is supply: outside the few countries where it is a licensed medicine, it reaches buyers through products not permitted to contain it, on labels that are often wrong. Much of the underlying pharmacology came from the company that developed and sold the compound, so the most favourable summaries of it carry a direct commercial interest. For someone optimising an already healthy brain, the evidence base is close to empty. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**